Gene · 8740
Papers1,880
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
641 to 660 of 1,880
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Comprehensive Analysis of TRP Channel-Related Genes in Patients With Triple-Negative Breast Cancer for Guiding Prognostic Prediction. | Front Oncol | 2022 | 35875096 | PubTator, text mining | PubMed |
| Single-Cell RNA Sequencing for Analyzing the Intestinal Tract in Healthy and Diseased Individuals. | Front Cell Dev Biol | 2022 | 35874838 | PubTator, text mining | PubMed |
| Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA Vaccination. | Front Immunol | 2022 | 35874675 | PubTator, text mining | PubMed |
| Apoptosis-Related Gene-Mediated Cell Death Pattern Induces Immunosuppression and Immunotherapy Resistance in Gastric Cancer. | Front Genet | 2022 | 35865012 | PubTator, text mining | PubMed |
| The m7G-Related Long Noncoding RNA Signature Predicts Prognosis and Indicates Tumour Immune Infiltration in Colon Cancer. | Front Genet | 2022 | 35846130 | PubTator, text mining | PubMed |
| SCG2: A Prognostic Marker That Pinpoints Chemotherapy and Immunotherapy in Colorectal Cancer. | Front Immunol | 2022 | 35844556 | PubTator, text mining | PubMed |
| Connecting aging biology and inflammation in the omics era. | J Clin Invest | 2022 | 35838044 | PubTator, text mining | PubMed |
| Identification of Alternative Splicing-Related Genes CYB561 and FOLH1 in the Tumor-Immune Microenvironment for Endometrial Cancer Based on TCGA Data Analysis. | Front Genet | 2022 | 35836577 | PubTator, text mining | PubMed |
| A comprehensive prognostic and immune analysis of enhancer RNA identifies IGFBP7-AS1 as a novel prognostic biomarker in Uterine Corpus Endometrial Carcinoma. | Biol Proced Online | 2022 | 35836132 | PubTator, text mining | PubMed |
| Sensory Nerves Impede the Formation of Tertiary Lymphoid Structures and Development of Protective Antimelanoma Immune Responses. | Cancer Immunol Res | 2022 | 35834791 | PubTator, text mining | PubMed |
| ALOX12: A Novel Insight in Bevacizumab Response, Immunotherapy Effect, and Prognosis of Colorectal Cancer. | Front Immunol | 2022 | 35833141 | PubTator, text mining | PubMed |
| Identification of Survival Risk and Immune-Related Characteristics of Kidney Renal Clear Cell Carcinoma. | J Immunol Res | 2022 | 35832648 | PubTator, text mining | PubMed |
| Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer. | J Big Data | 2022 | 35818395 | PubTator, text mining | PubMed |
| LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade. | J Immunol | 2022 | 35817517 | PubTator, text mining | PubMed |
| The Role of P4HA1 in Multiple Cancer Types and its Potential as a Target in Renal Cell Carcinoma. | Front Genet | 2022 | 35812752 | PubTator, text mining | PubMed |
| The trichloroethylene metabolite S-(1,2-dichlorovinyl)-l-cysteine inhibits lipopolysaccharide-induced inflammation transcriptomic pathways and cytokine secretion in a macrophage cell model. | Toxicol In Vitro | 2022 | 35811015 | PubTator, text mining | PubMed |
| Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma. | Mol Oncol | 2022 | 35810469 | PubTator, text mining | PubMed |
| CCL22-Polarized TAMs to M2a Macrophages in Cervical Cancer In Vitro Model. | Cells | 2022 | 35805111 | PubTator, text mining | PubMed |
| Oncolytic adenovirus promotes vascular normalization and nonclassical tertiary lymphoid structure formation through STING-mediated DC activation. | Oncoimmunology | 2022 | 35800155 | PubTator, text mining | PubMed |
| Integration and Reanalysis of Four RNA-Seq Datasets Including BALF, Nasopharyngeal Swabs, Lung Biopsy, and Mouse Models Reveals Common Immune Features of COVID-19. | Immune Netw | 2022 | 35799708 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8740/papers?page=33